Top Companies in the Cancer Supportive Care Drugs Market
- Amge
- Roche/Genentech
- Novartis
- Pfizer
- Johnson & Johnson
- Merck & Co.
- Eli Lilly
- Teva Pharmaceuticals
- Mylan (Viatris)
- Bristol-Myers Squibb
- AstraZeneca
- Takeda Pharmaceutical
- Helsinn Healthcare
- Kyowa Kirin
- Dr. Reddy’s Laboratories
- Fresenius Kabi
- Cipla
- Sun Pharma
- Hikma Pharmaceuticals
- Apotex
Cancer Supportive Care Drugs Market Growth:
The global cancer supportive care drugs market size is calculated at US$ 21.89 billion in 2024, grew to US$ 22.36 billion in 2025, and is projected to reach around US$ 27.05 billion by 2034. The market is expanding at a CAGR of 2.14% between 2025 and 2034.
What are the Trends in the Cancer Supportive Care Drugs Market?
- The supportive initiatives aim to address the growing cancer crisis in India through the establishment of specialized cancer care facilities in Delhi and Mumbai. For instance, in June 2025, Everhope Oncology launched $10 million in seed funding to transform cancer care in India.
- The recently launched cancer drugs are emerging as top sellers among new launches. For instance, in February 2025, Enhertu, an oncology drug marketed by AstraZeneca, UK, generated drug sales of Rs. 58 Crore within its first year of launch.
Value Chain Analysis
R&D
The R&D process for cancer supportive care drugs includes discovery, preclinical research, clinical trials, and expedited regulatory review.
Key Players: Novartis, AstraZeneca, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, AbbVie, Pfizer, Teva Pharmaceuticals, Bristol Myers Squibb Co
Clinical Trials and Regulatory Approvals
- The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) contribute to regulatory approvals for supportive cancer care drugs and expanded indications. Clinical trials are prioritizing symptom management, quality of life, and at-home care models.
Patient Support and Services
- The government programs, pharmaceutical patient assistance programs, non-profit organizations, hospital resources, global initiatives, and research contribute to patient support programs and related services. These services include financial assistance, patient navigation, psycho-social, and holistic support.
- Key Players: Amgen Inc., Novartis, Roche, Merck, Pfizer, Johnson & Johnson, etc.
Latest Announcements by Industry Leaders
- In April 2024, Courtney Bugler, President and CEO of ZERO Prostate Cancer of Novartis, said that people suffering from advanced cancers need advanced solutions through innovations that are important for patients and facilities. These inventions help them ensure promising healthcare delivery through treatments that are critical for patients.
Recent Developments in the Cancer Supportive Care Drugs Marketrn
- In April 2025, Pfizer Inc. highlighted its potential portfolio of cancer medicines at the 2025 annual meeting of the American Society of Clinical Oncology (ASCO).
- In May 2025, Merck announced that the Phase 3 KEYNOTE-B96 trial met the primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all-comers.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
